Influenza vaccine effectiveness against influenza A subtypes in Europe: Results from the 2021-2022 I-MOVE primary care multicentre study.
Esther KisslingFrancisco PozoIván Martínez-BazSilke BudaAna-Maria VilcuLisa DomeganClara MazagatosFrederika DijkstraNeus Latorre-MargalefSanja Kurečić FilipovićAusenda MachadoMihaela LazarItziar CasadoRalf DürrwaldSylvie van der WerfJoan O'DonnellJuan Antonio Linares DopidoAdam MeijerMaximilian RiessVesna Višekruna VučinaAna Paula RodriguesMaria Elena MihaiJesús CastillaLuise GoerlitzAlessandra FalchiJeff ConnellDaniel CastrillejoMariette HooiveldAnnasara CarnahanMaja IlićRaquel GuiomarAlina IvanciucMarine MaurelAjibola OmokanyeMarta Valencianonull nullPublished in: Influenza and other respiratory viruses (2022)
Despite antigenic mismatch between vaccine and circulating strains for influenza A(H3N2) and A(H1N1)pdm09, 2021-2022 VE estimates against circulating influenza A(H1N1)pdm09 were the highest within the I-MOVE network since the 2009 influenza pandemic. VE against A(H3N2) was lower than A(H1N1)pdm09, but at least one in five individuals vaccinated against influenza were protected against presentation to primary care with laboratory-confirmed influenza.